JP2014519317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519317A5 JP2014519317A5 JP2014509818A JP2014509818A JP2014519317A5 JP 2014519317 A5 JP2014519317 A5 JP 2014519317A5 JP 2014509818 A JP2014509818 A JP 2014509818A JP 2014509818 A JP2014509818 A JP 2014509818A JP 2014519317 A5 JP2014519317 A5 JP 2014519317A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- seq
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282326 Felis catus Species 0.000 claims description 33
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 20
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 20
- 229940053128 nerve growth factor Drugs 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 241000282324 Felis Species 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 45
- 239000012634 fragment Substances 0.000 claims 17
- 108091008604 NGF receptors Proteins 0.000 claims 3
- 101150111783 NTRK1 gene Proteins 0.000 claims 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483488P | 2011-05-06 | 2011-05-06 | |
| US61/483,488 | 2011-05-06 | ||
| US201161531439P | 2011-09-06 | 2011-09-06 | |
| US61/531,439 | 2011-09-06 | ||
| PCT/GB2012/051003 WO2012153122A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519317A JP2014519317A (ja) | 2014-08-14 |
| JP2014519317A5 true JP2014519317A5 (enExample) | 2016-07-21 |
| JP6258194B2 JP6258194B2 (ja) | 2018-01-10 |
Family
ID=46168540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509818A Active JP6258194B2 (ja) | 2011-05-06 | 2012-05-08 | 抗神経成長因子抗体並びに前記の製造及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9328164B2 (enExample) |
| EP (2) | EP2705055B1 (enExample) |
| JP (1) | JP6258194B2 (enExample) |
| KR (2) | KR20170070272A (enExample) |
| CN (1) | CN103732621B (enExample) |
| AU (1) | AU2012252152B2 (enExample) |
| BR (1) | BR112013028655B1 (enExample) |
| ES (1) | ES2704037T3 (enExample) |
| GB (1) | GB2504887B (enExample) |
| MY (1) | MY161394A (enExample) |
| RU (1) | RU2640254C2 (enExample) |
| SG (2) | SG194793A1 (enExample) |
| WO (1) | WO2012153122A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| KR20190112175A (ko) | 2010-12-01 | 2019-10-02 | 앨더바이오 홀딩스 엘엘씨 | 항―ｎｇｆ 조성물 및 그의 용도 |
| GB2528401A (en) | 2011-05-06 | 2016-01-20 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| GB201114858D0 (en) | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| EP2983711A4 (en) * | 2013-04-08 | 2016-11-23 | Cytodyn Inc | FELLINED ANTIBODIES AND METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES |
| CA2932515C (en) | 2013-12-20 | 2023-08-01 | Intervet International B.V. | Caninized antibodies |
| EP3201230B1 (en) | 2014-09-30 | 2020-12-23 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
| AU2016268625B2 (en) * | 2015-05-22 | 2022-01-27 | Astellas Pharma Inc. | Novel anti-human NGF antibody Fab fragment |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| WO2017102920A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| RU2744911C2 (ru) * | 2016-08-15 | 2021-03-17 | Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити | Антитело против pd-l1 |
| MX2019001896A (es) * | 2016-08-15 | 2019-08-29 | Univ Hokkaido Nat Univ Corp | Anticuerpo anti-pd-l1. |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| CA3093772C (en) | 2018-03-12 | 2024-04-16 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| CN110283246A (zh) * | 2019-06-20 | 2019-09-27 | 长春西诺生物科技有限公司 | 一种抗猫细小病毒的猫源化基因工程抗体 |
| EP4021499A4 (en) * | 2019-08-29 | 2024-08-07 | Elanco US Inc. | ANTI-IL31 ANTIBODIES FOR VETERINARY USE |
| WO2021176362A1 (en) * | 2020-03-03 | 2021-09-10 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| CA3218542A1 (en) | 2021-05-12 | 2022-11-17 | Hua Ying | Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof |
| EP4396237A4 (en) | 2021-08-31 | 2025-11-19 | Scout Bio Inc | Antigen-binding molecules and their uses |
| WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| KR20250151402A (ko) | 2023-01-20 | 2025-10-21 | 인베티엑스 인코포레이티드 | 반려 동물에서 사용하기 위한 이중특이적 결합제 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| CA2022959C (en) * | 1989-08-10 | 2001-03-20 | Hiroaki Maeda | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| GB9202796D0 (en) | 1992-02-11 | 1992-03-25 | Wellcome Found | Antiviral antibody |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1268794A2 (en) | 2000-04-07 | 2003-01-02 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US20030190705A1 (en) | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
| EP1485126A4 (en) * | 2001-12-21 | 2007-03-21 | Idexx Lab Inc | DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE |
| BRPI0407375A (pt) | 2003-02-19 | 2006-02-07 | Rinat Neuroscience Corp | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| PL1732949T3 (pl) * | 2004-04-07 | 2010-06-30 | Rinat Neuroscience Corp | Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| JP5440179B2 (ja) * | 2008-01-11 | 2014-03-12 | アステラス製薬株式会社 | 改良型ヒト化抗ヒトα９インテグリン抗体 |
| US8337842B2 (en) * | 2008-09-04 | 2012-12-25 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| EP2376122A2 (en) * | 2009-01-12 | 2011-10-19 | Takeda Pharmaceutical Company Limited | Agent for prophylaxis or treatment of cancer |
| US8569460B2 (en) | 2009-03-25 | 2013-10-29 | Vet Therapeutics, Inc. | Antibody constant domain regions and uses thereof |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| JP6121903B2 (ja) * | 2010-08-19 | 2017-04-26 | ゾエティス・ベルジャム・エス・アー | 抗ｎｇｆ抗体およびその使用 |
| EP3089967B1 (en) * | 2013-10-23 | 2022-03-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Small molecule imaging of fungi by positron emission tomography scanning |
-
2012
- 2012-05-08 CN CN201280033596.4A patent/CN103732621B/zh active Active
- 2012-05-08 KR KR1020177016066A patent/KR20170070272A/ko not_active Ceased
- 2012-05-08 SG SG2013081898A patent/SG194793A1/en unknown
- 2012-05-08 MY MYPI2013702080A patent/MY161394A/en unknown
- 2012-05-08 RU RU2013154301A patent/RU2640254C2/ru not_active Application Discontinuation
- 2012-05-08 AU AU2012252152A patent/AU2012252152B2/en active Active
- 2012-05-08 JP JP2014509818A patent/JP6258194B2/ja active Active
- 2012-05-08 EP EP12723731.1A patent/EP2705055B1/en active Active
- 2012-05-08 ES ES12723731T patent/ES2704037T3/es active Active
- 2012-05-08 WO PCT/GB2012/051003 patent/WO2012153122A1/en not_active Ceased
- 2012-05-08 EP EP18205428.8A patent/EP3498732B1/en active Active
- 2012-05-08 KR KR1020137032544A patent/KR101783929B1/ko active Active
- 2012-05-08 GB GB1320046.4A patent/GB2504887B/en active Active
- 2012-05-08 SG SG10201500953YA patent/SG10201500953YA/en unknown
- 2012-05-08 BR BR112013028655-5A patent/BR112013028655B1/pt active IP Right Grant
- 2012-05-08 US US14/115,787 patent/US9328164B2/en active Active
-
2016
- 2016-03-28 US US15/082,541 patent/US20160272701A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519317A5 (enExample) | ||
| JP2014519318A5 (enExample) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2019147801A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2020536532A5 (enExample) | ||
| JP2012526558A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2013535952A5 (enExample) | ||
| JP2014527814A5 (enExample) | ||
| JP2017502695A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2019532619A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2014522236A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2016188209A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2014530215A5 (enExample) |